China bans clinical research in germline genome editing as ‘irresponsible’
By Alcott Wei,
South China Morning Post
| 07. 13. 2024
China has banned all clinical research involving germline genome editing under a newly released ethics guideline.
Germline gene engineering relates to altering the DNA in sperm, eggs or early embryos to introduce changes that can be inherited.
“Any clinical research involving germline genome editing is irresponsible and not permitted,” according to the Ethical Guideline for Human Genome Editing Research, released earlier this week by China’s Ministry of Science and Technology.
The guideline marks the latest effort from China to tighten ethics reviews and regulations after bioscientist He Jiankui shocked the world in 2018 with the announcement that he had created twin gene-edited babies to make them less vulnerable to HIV/Aids.
“Only when benefits, risks and alternative options are fully understood and weighed, when issues of safety and efficacy are addressed, broad social consensus is reached and rigorous evaluation is conducted, could clinical research be considered with strict supervision in place,” the guideline adds.
It also strictly prohibits the use of genome editing research on germ cells, fertilised eggs, or human embryos for reproductive purposes.
“The potential detrimental impacts and risks...
Related Articles
By Samuelle Fajutrao Falk , The Conversation | 06.26.2026
When my colleagues and I asked autistic people and parents of autistic children in Sweden how they feel about genetic research in autism, one response stood out: “I hope genetic research finds new ways to help us, not erase us.”...
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Paul Knoepfler, Stat | 06.24.2026
What if you could precisely change the genome of a pre-implantation human embryo and then safely use that embryo to try to generate a healthier person? It’s a wild idea, but one that technology over the past decade has steadily...
